Cargando…

Vaccines

Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrie, Yvonne, Kaur, Randip, Henriksen-Lacey, Malou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120629/
http://dx.doi.org/10.1007/978-1-4614-9164-4_17
_version_ 1783515016281980928
author Perrie, Yvonne
Kaur, Randip
Henriksen-Lacey, Malou
author_facet Perrie, Yvonne
Kaur, Randip
Henriksen-Lacey, Malou
author_sort Perrie, Yvonne
collection PubMed
description Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vaccination may not be recognised. To address this, there has been a move towards the use of subunit-based vaccines, which offer low side-effect profiles but are generally weakly immunogenic. This can be compensated for by the development of effective adjuvants. Nanotechnology offers key attributes in this field through the ability of nanoparticulates to incorporate and protect antigens from rapid degradation, combined with their potential to effectively deliver the antigens to appropriate cells within the immune system. These characteristics can be exploited in the development of new adjuvants. This chapter will outline the applications of nanosystems in vaccine formulations and consider the mechanisms of action behind a range of formulations.
format Online
Article
Text
id pubmed-7120629
institution National Center for Biotechnology Information
language English
publishDate 2013
record_format MEDLINE/PubMed
spelling pubmed-71206292020-04-06 Vaccines Perrie, Yvonne Kaur, Randip Henriksen-Lacey, Malou Fundamentals of Pharmaceutical Nanoscience Article Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vaccination may not be recognised. To address this, there has been a move towards the use of subunit-based vaccines, which offer low side-effect profiles but are generally weakly immunogenic. This can be compensated for by the development of effective adjuvants. Nanotechnology offers key attributes in this field through the ability of nanoparticulates to incorporate and protect antigens from rapid degradation, combined with their potential to effectively deliver the antigens to appropriate cells within the immune system. These characteristics can be exploited in the development of new adjuvants. This chapter will outline the applications of nanosystems in vaccine formulations and consider the mechanisms of action behind a range of formulations. 2013-10-17 /pmc/articles/PMC7120629/ http://dx.doi.org/10.1007/978-1-4614-9164-4_17 Text en © Springer Science+Business Media New York 2013 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Perrie, Yvonne
Kaur, Randip
Henriksen-Lacey, Malou
Vaccines
title Vaccines
title_full Vaccines
title_fullStr Vaccines
title_full_unstemmed Vaccines
title_short Vaccines
title_sort vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120629/
http://dx.doi.org/10.1007/978-1-4614-9164-4_17
work_keys_str_mv AT perrieyvonne vaccines
AT kaurrandip vaccines
AT henriksenlaceymalou vaccines